Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Type 2 Diabetes

Every day, 5,225 new cases of diabetes are diagnosed in the U.S. alone, 90% to 95% of which are designated type 2 (T2D). T2D presents when the body either does not produce enough insulin or becomes resistant to insulin, resulting in high levels of blood sugar. The International Diabetes Federation estimates that 366 million adults worldwide suffered from T2D in 2011 and predicts this number will rise to 552 million by 2030; the Centers for Disease Control predicts that 25% to 33% of the U.S. adult population will have diabetes by 2050. It is estimated that pre-diabetes, or impaired glucose tolerance (IGT), a condition that often leads to diabetes, affects a population roughly twice the size of the current diabetes population. The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded $400 billion in 2010. United Healthcare expects spending on diabetes and diabetes-related care to reach $500 billion by 2020 in the U.S. alone, and projects
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... LOUIS , Aug. 19, 2014  Sequence, Inc., an ... for pharmaceutical, biotech and medical device manufacturers is opening a ... St. Louis , as a result of demand ... new location, which opened this month, allows Sequence to better ... Establishing a St. Louis office provides ...
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
(Date:8/19/2014)... , August 19, 2014 According ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and ... Growth, Trends and Forecast, 2014 - 2020", the global ... million in 2013 and is expected to grow at ... reach an estimated value of USD 295.5 million in ...
Breaking Medicine Technology:Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
... BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... biopharmaceutical products in China, announced today the positive top-line ... proprietary inactivated vaccine against human enterovirus 71 (EV71), which ... Phase II results for the EV71 vaccine showed a ...
... HARBIN, China, Nov. 9, 2011 /PRNewswire-Asia/ -- China Sky One ... CSKI ), a leading fully integrated pharmaceutical company producing ... announced financial results for the third quarter of 2011. ... Financial Highlights , Total revenues decreased 26.6% year-over-year to ...
Cached Medicine Technology:Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 2Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 3Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 4China Sky One Medical Announces Third Quarter 2011 Results 2China Sky One Medical Announces Third Quarter 2011 Results 3China Sky One Medical Announces Third Quarter 2011 Results 4China Sky One Medical Announces Third Quarter 2011 Results 5China Sky One Medical Announces Third Quarter 2011 Results 6China Sky One Medical Announces Third Quarter 2011 Results 7China Sky One Medical Announces Third Quarter 2011 Results 8China Sky One Medical Announces Third Quarter 2011 Results 9China Sky One Medical Announces Third Quarter 2011 Results 10China Sky One Medical Announces Third Quarter 2011 Results 11China Sky One Medical Announces Third Quarter 2011 Results 12China Sky One Medical Announces Third Quarter 2011 Results 13China Sky One Medical Announces Third Quarter 2011 Results 14China Sky One Medical Announces Third Quarter 2011 Results 15China Sky One Medical Announces Third Quarter 2011 Results 16China Sky One Medical Announces Third Quarter 2011 Results 17China Sky One Medical Announces Third Quarter 2011 Results 18
(Date:8/20/2014)... 2014 Inc. Magazine recently named ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ... as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, ... exposure as members of the Inc. 500|5000. , ...
(Date:8/20/2014)... 2014 Ticketability.com has Theresa ... fair prices. The well-known medium has been thrilling many ... touring in 19 cities, with tickets becoming available August ... will visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, ... Hills and San Diego. The medium’s fans can obtain ...
(Date:8/20/2014)... August 20, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers,restraints, challenges, opportunities, current market trends,and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:8/20/2014)... 20, 2014 GBK, the luxury lifestyle gift ... Award Nominees and Presenters at the annual GBK Gift Lounge. ... 23rd in Beverly Hills from 11am – 6pm. GBK will ... by DJ Morgan Hildebrand. , As always, GBK will blend ... several charities at the lounge. GO Campaign is a grantmaking ...
(Date:8/20/2014)... What to Do Now for UDI:, ... the Market, **FDAnews Webinar**, Sept. 11, 2014 — 1:30 ... Hospitals and other buyers of devices lose $5 billion ... systems. , Complying with the FDA’s deadlines is important, ... UDI as soon as possible. If devicemakers don’t, ...
Breaking Medicine News(10 mins):Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 2Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 3Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 4
... study , , MONDAY, Dec. 29 (HealthDay News) -- A ... natural and processed foods accelerated the growth of lung ... study suggests that dietary regulation of inorganic phosphates may ... prevention," Myung-Haing Cho, lead author of a report in ...
... among those whose families don,t accept them , , MONDAY, ... families rejected them when they were younger are more ... use and suicide attempts, new research suggests. , The ... a child,s sexuality directly causes problems later in life. ...
... Indulgence in a high-fat diet can not only ... also can affect the balance of circadian rhythms ... have shown. , The biological clock regulates the ... metabolism, and disturbance of the clock can lead to ...
... 29 Second Harvest Heartland, the,Upper Midwest,s largest ... Feeding America, General Mills and NBC,s "The Biggest ... pound participating dieters,in Minnesota and western Wisconsin pledge ... donate 10 cents to Second Harvest Heartland -- ...
... Ricinus communis is considered one of the most potent ... and inflammation and can result in death. Most accidental ... beans whereby the toxin is released after the seed ... damage with symptoms and death due to multiorgan failure ...
... NSAIDs and acetaminophen, are commonly used for the relief ... The gastrointestinal side effects of NSAIDs are well documented ... for the gastrointestinal system. Acute effects of short-term, especially ... adequately. , A research article to be published on ...
Cached Medicine News:Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Rejection of Gay Teens Linked to Later Troubles 2Health News:Rejection of Gay Teens Linked to Later Troubles 3Health News:Another reason to avoid high-fat diet -- it can disrupt our biological clock 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 3Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 4Health News:Acute gastric injury due to high-dose analgesics? 2
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... of cardiology catheters. Available in both Softouch ... with excellent torque, new wire-braid technology for ... large inner lumens for excellent flow rates. ... French sizes with pressure ratings up to ...
Medicine Products: